Cyltezo® (adalimumab-adbm) – Correction - high concentration formulation approved as biosimilar, not interchangeable
May 1, 2024 - Boehringer Ingelheim announced the FDA approval of Cyltezo (adalimumab-adbm) citrate-free, high concentration (40 mg/0.4 mL) injection, biosimilar to AbbVie’s Humira® (adalimumab).
Top